Some lymphoma medicines draw immune cells into the lymphoma, so lumps can swell and hurt for days or sometimes weeks. This is tumour flare, and it can look like the cancer growing when it is not. Painkillers and sometimes steroids are used. A lump near the windpipe or another vital organ can press on it, so tell your team straight away about swollen or sore lumps, chest pain or trouble breathing.
Tumour flare is a painful swelling of lymphoma sites, sometimes with new pleural effusions, low-grade fever or rash, in the first days to weeks of a T-cell-engaging bispecific antibody or of lenalidomide. The EU labels of all three bispecific antibodies say it is likely due to T cells moving into the tumour. It matters for two reasons: swelling next to an airway or vital organ can cause compression, and it can be mistaken for progression.
Rates and timing from the labels: glofitamab 12% (grade 3 in 2.8%), median onset 2 days after the first dose (range 1 to 16), median duration 3.5 days (range 1 to 35), almost all in cycle 1; mosunetuzumab 4% (US label) or 3.1% (EU label, median onset 13 days, median duration 36 days); epcoritamab 1.6% as monotherapy with a median onset of 19.5 days (EU label). On lenalidomide it was reported in 10% of patients in the mantle cell lymphoma trial (all grade 1 or 2, all in cycle 1), in 10.8% on lenalidomide with rituximab in the AUGMENT trial in follicular or marginal zone lymphoma (one grade 3), and in 4.1% in the MAGNIFY trial; one case in a separate mantle cell trial was fatal (US label). The US label says flare, including fatal reactions, occurred in investigational use for chronic lymphocytic leukaemia and lymphoma, and that lenalidomide is not indicated and not recommended for that leukaemia outside controlled trials.
Management is label-based. The US glofitamab and mosunetuzumab labels ask for close monitoring of people with bulky disease near an airway or vital organ during initial treatment, and all three EU labels ask for monitoring at critical anatomical sites; the US epcoritamab label gives no flare advice. The US glofitamab label withholds the drug for grade 2 to 4 flare and names an antihistamine and corticosteroids; the EU glofitamab label says corticosteroids and analgesics should be considered and has no hold rule for flare; the EU mosunetuzumab label withholds for grade 3 or 4 flare; the epcoritamab trial allowed treatment to continue through suspected flare. Lenalidomide may continue through grade 1 or 2 flare at the doctor's discretion, with NSAIDs, corticosteroids or opioid analgesics, and is withheld for grade 3 or 4 until it settles to grade 1 or less. A practice summary says flare can overlap with cytokine release syndrome and other toxicities, which are treated at the same time.
The LYRIC criteria, written for clinical trials, introduced an 'indeterminate response' category so that apparent progression on immune-modulating treatment is confirmed by biopsy or later imaging before it is called progression. No source read reports a trial comparing ways of managing flare. The reader's own team's protocol comes first.
Why: The label warns that flare can cause compression or obstruction, where a swollen mass presses on what lies beside it.
“Patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy.”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: The EU label says the patients at risk of tumour flare and tumour lysis are those with a high tumour burden before treatment.
“These patients should be monitored closely, especially during the first cycle or dose-escalation, and appropriate precautions taken.”
European Medicines Agency (marketing authorisation holder Bristol-Myers Squibb Pharma EEIG) 2007
Why: The US label reports more deaths on lenalidomide than on chlorambucil in a randomised trial in this leukaemia, and tumour flare reactions, some fatal, in investigational use for chronic lymphocytic leukaemia and lymphoma.
“REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials.”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023
Why: The US label asks that patients report signs such as localised pain and swelling for evaluation. The EU glofitamab leaflet lists tender swollen lymph nodes, chest pain, difficulty breathing and pain at the tumour site among the serious side effects to report straight away.
“Inform patients of the potential risk of tumor flare reaction and to report any signs and symptoms associated with this event (e.g., localized pain and swelling) to their healthcare provider for evaluation”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: These are the features the US glofitamab label and the US lenalidomide label describe.
“Manifestations include localized pain and swelling at the sites of the lymphoma lesions and/or dyspnea from new pleural effusions.”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: On glofitamab flare started a median of 2 days after the first dose (range 1 to 16) and lasted a median of 3.5 days (range 1 to 35). The EU labels give a median onset of 13 days for mosunetuzumab and 19.5 days for epcoritamab.
“Most tumor flare events occurred during Cycle 1, with a median time to first onset of 2 days (range: 1 to 16 days) after the first dose of COLUMVI.”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: The EU glofitamab label and both lenalidomide labels say flare may mimic progression of disease. The LYRIC authors add that calling it progression could take people off a treatment they stand to benefit from.
“Tumour flare does not imply treatment failure or represent tumour progression.”
European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023
Why: LYRIC is a set of provisional recommendations written for clinical trials, and its abstract names checkpoint inhibitors rather than bispecific antibodies. Only the abstract could be read.
“The term "indeterminate response" was introduced to identify such lesions until confirmed as flare/pseudo-progression or true PD by either biopsy or subsequent imaging.”
Why: A one-page practice summary says tumour flare, tumour lysis, low blood counts and immune compromise can have overlapping features with cytokine release syndrome and neurotoxicity, and that treatment should occur simultaneously.
“They can have overlapping clinical manifestations with CRS and ICANS, and treatment should occur simultaneously.”
CMAJ (Britto et al.; three authors declare research funding or honoraria from drug companies) 2025
Why: The US mosunetuzumab and glofitamab labels both ask for this monitoring. The EU labels describe a heightened risk of compromise and morbidity from mass effect where bulky tumours lie close to an airway or vital organ.
“If compression or obstruction develops, institute standard treatment of these complications.”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: Of 11 patients with grade 2 or higher flare in the glofitamab trial, 2 had analgesics alone, 6 had corticosteroids and analgesics, 1 had corticosteroids and anti-emetics and 2 needed no treatment (EU label). No label read gives a steroid drug or dose.
“Corticosteroids and analgesics should be considered to treat tumour flare.”
European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023
Why: The US label gives this rule in its dose-modification table without a stated reason; grade 1 flare is monitored without a hold. The EU glofitamab label has no hold rule for flare.
“Withhold COLUMVI until tumor flare resolves.”
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026
Why: The EU label names tumour flare among the grade 3 or 4 reactions that call for a pause. The US label has no row for flare; its general rule withholds for any other grade 3 or higher reaction until it is grade 1 or baseline.
“Patients who experience grade 3 or 4 reactions (e.g. serious infection, tumour flare, tumour lysis syndrome) should have treatment temporarily withheld until symptoms are resolved (see section 4.4).”
European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2022
Why: Both labels allow lenalidomide to continue without interruption or dose change through grade 1 or 2 flare. In the mantle cell lymphoma trial all reports were grade 1 or 2.
“REVLIMID may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physician's discretion.”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023
Why: Tumour flare reactions on lenalidomide have included fatal ones. The EU label adds NSAIDs, corticosteroids or narcotic analgesics during the hold, and a restart at the same dose level for the rest of the cycle.
“In patients with Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to ≤ Grade 1.”
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
There is no graded guideline on tumour flare that could be read; the best supported practice is what the labels share. Identify bulky disease and disease next to an airway or vital organ before the first dose and monitor those patients closely during initial treatment (US glofitamab and mosunetuzumab labels; the three EU labels ask for monitoring at critical anatomical sites; the US epcoritamab label is silent); tell patients the signs to report; consider corticosteroids and analgesics for symptoms; start standard treatment if compression or obstruction develops; and do not call early swelling progression on appearance alone (EU glofitamab label; LYRIC, for trials). The labels differ on whether to pause treatment, and each position is shown: the US glofitamab label withholds for grade 2 to 4 flare, the EU mosunetuzumab label for grade 3 or 4, the EU glofitamab label asks only for management as clinically indicated, and the epcoritamab trial allowed treatment to continue. For lenalidomide both labels allow treatment to continue through grade 1 or 2 flare at the doctor's discretion and withhold it for grade 3 or 4.
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023 · Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2022 · European Medicines Agency (marketing authorisation holder AbbVie Deutschland GmbH & Co. KG) 2023 · Genmab US (DailyMed, US National Library of Medicine) 2026 · Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023 · European Medicines Agency (marketing authorisation holder Bristol-Myers Squibb Pharma EEIG) 2007 · Blood (Cheson et al.) 2016
Where it differs: The US glofitamab label withholds for grade 2 to 4 flare until it resolves and only monitors grade 1. The EU glofitamab label gives no hold rule for flare and says to manage as clinically indicated. The EU mosunetuzumab label withholds for grade 3 or 4 flare until symptoms resolve; the US mosunetuzumab label asks for monitoring and standard treatment of any compression and has no flare row in its dose table. The US epcoritamab label has no tumour flare warning; its trial description says continued treatment was permitted in suspected flare. The US mosunetuzumab and epcoritamab labels and the EU epcoritamab label each carry a general rule to withhold for other grade 3 or higher adverse reactions until grade 1 or baseline, which does not name flare.
Evidence: Label text from single-arm trials. In the glofitamab trial no patient stopped treatment because of flare and all but one event resolved (EU label).
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023 · Genmab US (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder AbbVie Deutschland GmbH & Co. KG) 2023 · Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2022
Where it differs: For grade 2 to 4 flare the US glofitamab label names an antihistamine and corticosteroids. The EU label says corticosteroids and analgesics should be considered. A literature review, writing about flare on lenalidomide in chronic lymphocytic leukaemia, lists analgesics, NSAIDs, antihistamines and corticosteroids.
Evidence: Descriptive only. Of 11 patients with grade 2 or higher flare on glofitamab, 2 had analgesics alone, 6 had corticosteroids with analgesics including morphine derivatives, 1 had corticosteroids with anti-emetics and 2 needed no treatment (EU label).
Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 · European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023 · Anti-Cancer Drugs (Taleb) 2019
Where it differs: The US label recommends withholding for grade 3 or 4 flare until it is grade 1 or less. The EU label adds NSAIDs, corticosteroids or narcotic analgesics during the hold and a restart at the same dose level for the rest of the cycle, and for grade 1 or 2 flare says the corticosteroids are of limited duration. The EU label also names who is at risk in mantle cell lymphoma: a high MIPI score at diagnosis or bulky disease, defined as a lesion of 7 cm or more.
Evidence: Label rules. Flare was reported in 13 of 134 patients (10%) in the mantle cell trial and 19 of 176 (10.8%) on lenalidomide with rituximab in AUGMENT; one case in a separate mantle cell trial was fatal (US label). The EU label gives 19 of 146 (13.0%) for its study NHL-007.
Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023 · European Medicines Agency (marketing authorisation holder Bristol-Myers Squibb Pharma EEIG) 2007
Where it differs: A Canadian expert working group on bispecific antibodies for DLBCL, funded by Hoffmann-La Roche, gives no flare rules of its own and endorses the product monographs and the Crombie 2024 consensus for tumour flare.
Evidence: Expert opinion. The Crombie consensus itself could be read as an abstract only.
Current Oncology (MacDonald et al.; research and publication charge funded by Hoffmann-La Roche Ltd) 2025 · Blood (Crombie et al.) 2024
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Glofitamab: tumour flare in 12%, grade 3 in 2.8%, recurrent in two patients “Tumor flare was reported in 12% of patients who received COLUMVI, including Grade 2 tumor flare in 4.8% of patients and Grade 3 tumor flare in 2.8%.” | Regulatory label; not graded | Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 |
| Glofitamab, grade 2 to 4 flare: antihistamine and corticosteroids “Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare, and institute appropriate treatment including antihistamine and corticosteroids.” | Regulatory label; not graded | Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 |
| Glofitamab (EU): flare may mimic progression and is attributed to T cells entering the tumour “tumour flare is likely due to the influx of T cells into tumour sites following Columvi administration and may mimic progression of disease.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2023 |
| Mosunetuzumab: flare in 4%, with new or worsening pleural effusions, pain and swelling “Among patients who received LUNSUMIO at the recommended dosage in the clinical trial, tumor flare occurred in 4%.” | Regulatory label; not graded | Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine) 2026 |
| Mosunetuzumab (EU): flare in 3.1%, grade 3 in 1.4% “tumour flare (including pleural effusion and tumour inflammation) occurred in 3.1% (11/357) of patients, which included 1.4% grade 2 and 1.4% grade 3 events.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2022 |
| Mosunetuzumab (EU): monitor at critical anatomical sites “Lunsumio should be monitored and evaluated for tumour flare at critical anatomical sites.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder Roche Registration GmbH) 2022 |
| Epcoritamab (EU): monitor at critical anatomical sites “epcoritamab should be monitored and evaluated for tumour flare at critical anatomical sites.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder AbbVie Deutschland GmbH & Co. KG) 2023 |
| Epcoritamab (EU): flare in 1.6% on monotherapy, all grade 2 “In study GCT3013-01, tumour flare occurred in 1.6% (6/382) of patients, all of which were grade 2.” | Regulatory label; not graded | European Medicines Agency (marketing authorisation holder AbbVie Deutschland GmbH & Co. KG) 2023 |
| Epcoritamab (US): treatment could continue in suspected flare in the trial “In the setting of a suspected tumor flare reaction, continued treatment was permitted.” | Regulatory label; not graded | Genmab US (DailyMed, US National Library of Medicine) 2026 |
| Lenalidomide: flare may mimic progression; monitoring recommended in mantle cell, follicular and marginal zone lymphoma “Monitoring and evaluation for TFR is recommended in patients with MCL, FL, or MZL. Tumor flare reaction may mimic progression of disease (PD).” | Regulatory label; not graded | Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023 |
| Lenalidomide: symptom treatment for grade 1 and 2 flare “Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms.” | Regulatory label; not graded | Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine) 2023 |
| Canadian guidance defers to the product monographs and the 2024 consensus for tumour flare “The EWG endorse recommendations from the respective product monographs and Crombie et al. (2024) for the management of non-CRS AEs” | Expert working group, funded by Roche; not graded | Current Oncology (MacDonald et al.; research and publication charge funded by Hoffmann-La Roche Ltd) 2025 |
Shares T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery, Mosunetuzumab, Epcoritamab, Glofitamab.
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Marginal zone lymphoma.
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Marginal zone lymphoma.
Shares T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery, Mosunetuzumab, Epcoritamab, Glofitamab.
Shares Tumour lysis syndrome: risk assessment, prophylaxis and treatment, Tumour lysis syndrome (TLS), Mantle cell lymphoma, Diffuse large B-cell lymphoma.
Shares Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Mosunetuzumab, Epcoritamab, Glofitamab.
Shares Mosunetuzumab, Epcoritamab, Glofitamab, Cytokine release syndrome (CRS).
Shares T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Cytokine release syndrome (CRS).